bluebird bio, Inc. (BLUE) News

bluebird bio, Inc. (BLUE): $29.96

0.29 (+0.98%)

POWR Rating

Component Grades













Add BLUE to Watchlist
Sign Up

Industry: Biotech


of 492

in industry

Filter BLUE News Items

BLUE News Results

Date Symbol Company Title Start End Change POWR Rating
Loading, please wait...

BLUE News Highlights

  • For BLUE, its 30 day story count is now at 10.
  • Over the past 15 days, the trend for BLUE's stories per day has been choppy and unclear. It has oscillated between 1 and 3.
  • BIO, GENE and AGE are the most mentioned tickers in articles about BLUE.

Latest BLUE News From Around the Web

Below are the latest news stories about bluebird bio Inc that investors may wish to consider to help them evaluate BLUE as an investment opportunity.

bluebird bio Reports First Quarter Financial Results and Highlights Operational Progress

bluebird bio, Inc. (NASDAQ: BLUE) today reported financial results and business highlights for the first quarter ended March 31, 2021 and shared recent operational progress.

Yahoo | May 5, 2021

Checking In on 3 Stock Samplers

In this episode of Rule Breaker Investing, we review 5 Stocks for the Coronavirus, 5 Stocks for the Age of Miracles, and 5 Stocks I Own That You Should, Too. To catch full episodes of all The Motley Fool's free podcasts, check out our podcast center. David Gardner: Last April, the market was in as dark a place as any of us have seen for more than 10 years -- the 35% loss of the S&P 500 in 32 days.

Yahoo | May 3, 2021

Bluebird Bio (BLUE) Expected to Beat Earnings Estimates: What to Know Ahead of Q1 Release

Bluebird (BLUE) possesses the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

Yahoo | May 3, 2021

bluebird bio Announces May Investor Events

bluebird bio, Inc. (NASDAQ: BLUE) today announced that members of the management team will participate in the following upcoming investor conferences:

Yahoo | May 3, 2021

What Investors Need to Know About This $419,500 CAR-T Cancer Treatment

Bristol Myers Squibb (NYSE: BMY) and bluebird bio (NASDAQ: BLUE) recently gained Food and Drug Administration approval of Abecma. In this video from Motley Fool Live, recorded on March 29, Contributors Brian Orelli and Keith Speights discuss the prospects for Abecma and what the companies are doing to increase the potential market for the chimeric antigen receptor T-cell (CAR-T) product. Brian Orelli: On Friday, the FDA approved Bristol Myers Squibb and Bluebird Bio's CAR-T treatment for multiple myeloma.

Yahoo | May 1, 2021

Will Vertex's Sickle Cell Gambit Sink bluebird bio's Stock?

Last week, Vertex Pharmaceuticals (NASDAQ: VRTX) announced that it would pay CRISPR Therapeutics (NASDAQ: CRSP) a whopping $900 million to take more control of the duo's gene therapy collaboration, CTX001. CTX001 is being investigated as a potentially curative treatment for severe sickle cell disease and beta thalassemia, a rare blood disorder. Beti-cel is already on the market in the EU for beta thalassemia, but Bluebird is still facing a slew of problems in the U.S. and in major European markets.

Yahoo | May 1, 2021

Here's How Investors Can Find Strong Medical Stocks with the Zacks ESP Screener

Investors looking for ways to find stocks that are set to beat quarterly earnings estimates should check out the Zacks Earnings ESP.

Yahoo | April 21, 2021

Analysts' Revenue Estimates For bluebird bio, Inc. (NASDAQ:BLUE) Are Surging Higher

bluebird bio, Inc. ( NASDAQ:BLUE ) shareholders will have a reason to smile today, with the analysts making substantial...

Yahoo | April 21, 2021

Bluebird bio price target slashed at Stifel after setback in Germany

The decision by bluebird bio ([[BLUE]] +0.1%) to withdraw Zynteglo (betibeglogene autotemcel) for transfusion-dependent β-thalassemia (“TDT”) from the German market did not come as a surprise.A Suspected Unexpected Serious Adverse Reaction (SUSAR) of acute myeloid leukemia (AML) forced a temporary suspension of two clinical trials in sickle cell disease for its...

Seeking Alpha | April 20, 2021

bluebird bio Provides Update on Severe Genetic Disease Programs and Business Operations

bluebird bio, Inc. (Nasdaq: BLUE) announced today business and program updates across its severe genetic disease portfolio including a revised diagnosis for the previously reported case of myelodysplastic syndrome (MDS) in its Phase 1/2 study of LentiGlobin for sickle cell disease (SCD) (bb1111), the company’s decision to withdraw ZYNTEGLO™ (betibeglogene autotemcel, beti-cel) for transfusion-dependent β-thalassemia (TDT) from the German market and a targeted reshaping of its workforce intended to enable the company to advance its late-stage gene therapy programs.

Yahoo | April 20, 2021

Get Free Updates

Join thousands of investors who get the latest news, insights and top rated picks from!

Page generated in 0.7146 seconds.